Recent Publications
Waller LL, Miller AA, Streer NP, Lovato JF, Petty WJ.
Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC [abstract]. J Clin Oncol.
2011;
29(Suppl):abstr 7601.
Ruiz J, Chou J, Geisinger KR, Schoppe CH, Miller AA, Willingham MC, Petty WJ, Bolemon BH, Miller LD.
Microarray gene expression patterns recapitulated on a clinically tractable diagnostic platform using breast and lung cancer formalin-fixed paraffin-embedded tissues [abstract]. J Clin Oncol.
2011;
29(Suppl):e21027.
Ruiz J, Miller AA, Petty WJ, Chou JW, Miller LD.
A novel prognostic transcriptional signature for early stage non-small cell lung cancer [abstract]. J Thorac Oncol.
2010;
5(12 Suppl 7):S505.
Petty WJ, Miller AA, Aklilu M, McCoy TP, Swift CB, Torti FM.
The tumor tissue renin-angiotensin system as a target for cancer therapy [abstract]. Int J Mol Med.
2010;
26(Suppl 1):S19.
Waller LL, Miller AA, Streer NP, McCoy TP, Petty WJ.
Overcoming pharmacokinetic resistance to erlotinib: rationale and preliminary findings from a phase II study [abstract]. J Thorac Oncol.
2010;
5(6 Suppl 3):S247-S248.
Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, Lilenbaum R, Niell HB, Maurer LH, Kosty MP, Miller AA, et al.
Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol.
2010;
28(2):215-221.
Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, et al.
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol.
2009;
27(11):1800-1805.
Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, Wilson LD, Horton JK, Detterbeck FC, Miller AA, Blackstock AW, et al.
Trends in the outcomes for patients with limited stage small cell lung cancer: an analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer.
2009;
64(2):226-231.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Phase I study of angiotensin-(1-7), an endogenous antiangiogenic hormone: clinical, pharmacokinetic, and biomarker findings [abstract]. Mol Cancer Ther.
2009;
8(12 Suppl 1):B208.
Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Vokes EE.
A Phase II study of dasatinib in patients with chemo-sensitive relapsed small cell lung cancer (SCLC): CALGB 30602 [abstract]. J Thorac Oncol.
2009;
4(9 Suppl 1):S816-S817.
Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Sleeper A, Miller AA, et al.
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol.
2008;
26(15):2457-2463.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Phase I trial of angiotensin-(1-7): an endogenous anti-angiogenic hormone [abstract]. J Clin Oncol.
2008;
26(15 Suppl):634s.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR.
2008;
():Abstr 4968.
Blackstock A, Petty J, Oaks T, Porosnicu M, Clark H, Lovato J, Miller A.
Gefitinig (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. J Clin Oncol.
2007;
25(18 Suppl):Abstr18165.
Lally BE, Detterbeck FC, Geiger AM, Thomas CR Jr, Machtay M, Miller AA, Oaks TE, Petty WJ, Robbins ME, Blackstock AW, et al.
The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer.
2007;
110(4):911-917.
Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, et al.
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol.
2007;
25(21):3055-3060.
Blackstock AW, Jensen CA, Petty WJ, Oaks T, Porosnicu M, Clark H, Lovato JF, Miller A.
Gefitinib (ZD-1839) with concurrent docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel/gefitinib for patients with stage III NSCLC: a phase I study [abstract]. Int J Radiat Oncol Biol Phys.
2007;
69(3 Suppl):S476.
Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, et al.
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and caucasian cancer patients: CALGB 9871. Clin Cancer Res.
2007;
13(11):3302-3311.
All Publications
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.